The DOI matches its Crossref record; 428 of the 428 references it cites were found in a registry or an index.
Mechanisms of action of glucagon-like peptide 1 in the pancreas
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crystal Structure of Rhodopsin: A G Protein-Coupled Receptor
Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Trong, I. L., Teller, D. C., Okada, T., Stenkamp, R. E., et al. (2000) · Science · doi:10.1126/science.289.5480.739 · Cited by 5,637
Insulin signalling and the regulation of glucose and lipid metabolism
Saltiel, A. R., & Kahn, C. R. (2001) · Nature · doi:10.1038/414799a · Cited by 5,326
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Srimaroeng, C., Cecile, J. P., Walden, R., & Pritchard, J. B. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350077 · Cited by 2,989
Fetal and infant growth and impaired glucose tolerance at age 64
Hales, C. N., Barker, D. J., Clark, P. M., Cox, L. J., Fall, C., Osmond, C., & Winter, P. D. (1991) · BMJ · doi:10.1136/bmj.303.6809.1019 · Cited by 2,708
SNAREs — engines for membrane fusion
Jahn, R., & Scheller, R. H. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2002 · Cited by 2,635
TRANSCRIPTION FACTORS OF THE NFAT FAMILY:Regulation and Function
Rao, A., Luo, C., & Hogan, P. G. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.707 · Cited by 2,603
Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133
Gonzalez, G. A., & Montminy, M. R. (1989) · Cell · doi:10.1016/0092-8674(89)90013-5 · Cited by 2,464
Adult pancreatic β-cells are formed by self-duplication rather than stem-cell differentiation
Dor, Y., Brown, J., Martinez, O. I., & Melton, D. A. (2004) · Nature · doi:10.1038/nature02520 · Cited by 2,219
Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP
de Rooij, J., Zwartkruis, F. J. T., Verheijen, M. H. G., Cool, R. H., Nijman, S. M. B., Wittinghofer, A., & Bos, J. L. (1998) · Nature · doi:10.1038/24884 · Cited by 1,969
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
“Glucagon, for example, binds GLP-1R with 100- to 1000-fold less affinity than does GLP-1 (Thorens, 1992; Fehmann et al., 1994; Doyle and Egan, 2007).”
BackgroundInfluentialSelf-citationO'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31773-2 · Cited by 814
Regulation of Insulin Synthesis and Secretion and Pancreatic Beta-Cell Dysfunction in Diabetes
Fu, Z., R. Gilbert, E., & Liu, D. (2013) · Current Diabetes Reviews · doi:10.2174/157339913804143225 · Cited by 732
Epac: Defining a New Mechanism for cAMP Action
Gloerich, M., & Bos, J. L. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105714 · Cited by 473
The New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes
Ahrén, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2782 · Cited by 419
Meloni, A. R., DeYoung, M. B., Lowe, C., & Parkes, D. G. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01663.x · Cited by 407
Kodera, R., Shikata, K., Kataoka, H. U., Takatsuka, T., Miyamoto, S., Sasaki, M., Kajitani, N., Nishishita, S., Sarai, K., Hirota, D., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-2028-x · Cited by 394
A chemical-genetic approach to study G protein regulation of β cell function in vivo
Guettier, J.-M., Gautam, D., Scarselli, M., de Azua, I. R., Li, J. H., Rosemond, E., Ma, X., Gonzalez, F. J., Armbruster, B. N., Lu, H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906593106 · Cited by 344
de la Monte, S. M. (2017) · Drugs · doi:10.1007/s40265-016-0674-0 · Cited by 331
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
“These two effectors of cAMP signaling modify several targets within the secretory machinery, with the net effect to synergistically enhance the amount of insulin secreted in response to glucose stimulation (15, 16).”
BackgroundThe structure and function of the glucagon‐like peptide‐1 receptor and its ligands
Donnelly, D. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01687.x · Cited by 292
Shu, L., Matveyenko, A. V., Kerr-Conte, J., Cho, J.-H., McIntosh, C. H. S., & Maedler, K. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp178 · Cited by 270
Schmidt, M., Dekker, F. J., & Maarsingh, H. (2013) · Pharmacological Reviews · doi:10.1124/pr.110.003707 · Cited by 267
Recent updates on GLP-1 agonists: Current advancements & challenges
Sharma, D., Verma, S., Vaidya, S., Kalia, K., & Tiwari, V. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.088 · Cited by 265
Oxidative and endoplasmic reticulum stress in β-cell dysfunction in diabetes
Hasnain, S. Z., Prins, J. B., & McGuckin, M. A. (2016) · Journal of Molecular Endocrinology · doi:10.1530/jme-15-0232 · Cited by 253
Sonoda, N., Imamura, T., Yoshizaki, T., Babendure, J. L., Lu, J.-C., & Olefsky, J. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710402105 · Cited by 239
Chuong, V., Farokhnia, M., Khom, S., Pince, C. L., Elvig, S. K., Vlkolinsky, R., Marchette, R. C. N., Koob, G. F., Roberto, M., Vendruscolo, L. F., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.170671 · Cited by 214
Hamilton, A., Patterson, S., Porter, D., Gault, V. A., & Holscher, C. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22565 · Cited by 210
GLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation
Shigeto, M., Ramracheya, R., Tarasov, A. I., Cha, C. Y., Chibalina, M. V., Hastoy, B., Philippaert, K., Reinbothe, T., Rorsman, N., Salehi, A., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81975 · Cited by 189
Brain insulin resistance: role in neurodegenerative disease and potential for targeting
Hölscher, C. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1738383 · Cited by 180
Hadjiyanni, I., Siminovitch, K. A., Danska, J. S., & Drucker, D. J. (2010) · Diabetologia · doi:10.1007/s00125-009-1643-x · Cited by 166
“GLP-1R activation leads to cAMP production in primary immune cells GLP-1R activation is coupled to cAMP accumulation in multiple cell types [ 21 ].”
BackgroundCornell, S. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13230 · Cited by 156
Sharma, M. K., Jalewa, J., & Hölscher, C. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12469 · Cited by 151
Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue
Russell-Jones, D. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.11.018 · Cited by 137
Kim, J.-Y., Lee, S.-K., Jo, K.-J., Song, D.-Y., Lim, D.-M., Park, K.-Y., Bonewald, L. F., & Kim, B.-J. (2013) · Life Sciences · doi:10.1016/j.lfs.2013.01.001 · Cited by 137
Mechanistic links between gut microbial community dynamics, microbial functions and metabolic health
Ha, C. W. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i44.16498 · Cited by 137
Ramracheya, R., Chapman, C., Chibalina, M., Dou, H., Miranda, C., González, A., Moritoh, Y., Shigeto, M., Zhang, Q., Braun, M., et al. (2018) · Physiological Reports · doi:10.14814/phy2.13852 · Cited by 128
Perna, S., Guido, D., Bologna, C., Solerte, S. B., Guerriero, F., Isu, A., & Rondanelli, M. (2016) · Aging Clinical and Experimental Research · doi:10.1007/s40520-015-0525-y · Cited by 125
Wang, Z.-J., Li, X.-R., Chai, S.-F., Li, W.-R., Li, S., Hou, M., Li, J.-L., Ye, Y.-C., Cai, H.-Y., Hölscher, C., et al. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109716 · Cited by 125
Ronveaux, C. C., Tomé, D., & Raybould, H. E. (2015) · The Journal of Nutrition · doi:10.3945/jn.114.206029 · Cited by 124
Ramos, L. S., Zippin, J. H., Kamenetsky, M., Buck, J., & Levin, L. R. (2008) · The Journal of General Physiology · doi:10.1085/jgp.200810044 · Cited by 118
Wang, C., Li, L., Liu, S., Liao, G., Li, L., Chen, Y., Cheng, J., Lu, Y., & Liu, J. (2018) · PLOS ONE · doi:10.1371/journal.pone.0193473 · Cited by 110
Wang, X.-C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i40.14821 · Cited by 109
Incretins in obesity and diabetes
Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93
Self-citationMazidi, M., Karimi, E., Rezaie, P., & Ferns, G. A. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.05.022 · Cited by 89
Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
Giugliano, D., Sportiello, L., Capuano, A., Maiorino, M., Rossi, F., & Esposito, K. (2013) · Drug Design, Development and Therapy · doi:10.2147/dddt.s37647 · Cited by 86
Klinger, S., Poussin, C., Debril, M.-B., Dolci, W., Halban, P. A., & Thorens, B. (2008) · Diabetes · doi:10.2337/db07-1414 · Cited by 86
The effects of dual GLP-1/GIP receptor agonism on glucagon secretion-A Review
Mathiesen, D. S., Bagger, J. I., Bergmann, N. C., Lund, A., Christensen, M. B., Vilsbøll, T., & Knop, F. K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174092 · Cited by 80
Long acting GLP-1 analog liraglutide ameliorates skeletal muscle atrophy in rodents
Gurjar, A. A., Kushwaha, S., Chattopadhyay, S., Das, N., Pal, S., China, S. P., Kumar, H., Trivedi, A. K., Guha, R., Chattopadhyay, N., et al. (2020) · Metabolism · doi:10.1016/j.metabol.2019.154044 · Cited by 79
The Role of GLP-1 in Neuronal Activity and Neurodegeneration
Hölscher, C. (2010) · Vitamins & Hormones · doi:10.1016/b978-0-12-381517-0.00013-8 · Cited by 74
GLP‐1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities
Roth, J. D., Erickson, M. R., Chen, S., & Parkes, D. G. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01537.x · Cited by 74
Liraglutide Improves Pancreatic Beta Cell Mass and Function in Alloxan-Induced Diabetic Mice
Tamura, K., Minami, K., Kudo, M., Iemoto, K., Takahashi, H., & Seino, S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126003 · Cited by 70
Sancar-Bas, S., Gezginci-Oktayoglu, S., & Bolkent, S. (2015) · Growth Factors · doi:10.3109/08977194.2015.1125349 · Cited by 71
Jun, L. S., Millican, R. L., Hawkins, E. D., Konkol, D. L., Showalter, A. D., Christe, M. E., Michael, M. D., & Sloop, K. W. (2015) · Diabetes · doi:10.2337/db14-1052 · Cited by 60
“Use of the Gcgr, Glp-1r, and Gcgr:Glp-1r genetic models here builds on previous work in Gcgr mice showing that administration of the GLP-1R peptide antagonist, exendin-4(9-39), worsens glucose tolerance in these animals (19).”
BackgroundMethodResultInfluentialDalle, S., Burcelin, R., & Gourdy, P. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2012.11.009 · Cited by 60
Gotfredsen, C. F., Mølck, A.-M., Thorup, I., Nyborg, N. C. B., Salanti, Z., Knudsen, L. B., & Larsen, M. O. (2014) · Diabetes · doi:10.2337/db13-1087 · Cited by 60
Wai, K. M., Mishra, K., Koo, E., Ludwig, C. A., Parikh, R., Mruthyunjaya, P., & Rahimy, E. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.04.010 · Cited by 61
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025) · Biomolecules · doi:10.3390/biom15030408 · Cited by 58
“A synthetic version of exendin-4 was approved by the FDA in 2005 for glycemic control in type 2 diabetics [145,146].”
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer
Ibrahim, S. S., Ibrahim, R. S., Arabi, B., Brockmueller, A., Shakibaei, M., & Büsselberg, D. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10192-9 · Cited by 56
Discovery of ecnoglutide - a novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog
Guo, W., Xu, Z., Zou, H., Li, F., Li, Y., Feng, J., Zhu, Z., Zheng, Q., Zhu, R., Wang, B., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101762 · Cited by 58
Kaur, M., & Misra, S. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03646-0 · Cited by 51
Zhang, F., Chen, Z., Wu, D., Tian, L., Chen, Q., Ye, Y., Chen, W., Wu, X., Wu, P., Yuan, W., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103382 · Cited by 54
Zhao, T. C. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-90 · Cited by 45
Li, L., Zhang, L.-Y., Jin, Q.-Q., & Hölscher, C. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.303045 · Cited by 38
Glucagon‐like peptide‐1: modulator of β ‐cell dysfunction and death
Rondas, D., D'Hertog, W., Overbergh, L., & Mathieu, C. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12165 · Cited by 32
Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
AL-Noshokaty, T. M., Abdelhamid, R., Abdelmaksoud, N. M., Khaled, A., Hossam, M., Ahmed, R., Saber, T., Khaled, S., Elshaer, S. S., & Abulsoud, A. I. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.101895 · Cited by 30
Zhang, X., Cao, C., Zheng, F., Liu, C., & Tian, X. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07670-9 · Cited by 27
“These factors have been demonstrated to enhance both β-cell proliferation and α-to-β-cell trans-differentiation [38–40].”
Effects on pancreatic Beta and other Islet cells of the glucose-dependent insulinotropic polypeptide
Khan, R., Tomas, A., & Rutter, G. A. (2020) · Peptides · doi:10.1016/j.peptides.2019.170201 · Cited by 24
Rodgers, M., Migdal, A. L., Rodríguez, T. G., Chen, Z.-Z., Nath, A. K., Gerszten, R. E., Kasid, N., Toschi, E., Tripaldi, J., Heineman, B., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.742873 · Cited by 24
“Exenatide, the first approved GLP1RA, was developed for the treatment of type 2 diabetes (7).”
BackgroundGao, L., Huang, H., Zhang, L., Zhang, N., Fu, Y., Zhu, D., Bi, Y., & Feng, W. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1608-0345 · Cited by 24
PKA Enhances the Acute Insulin Response Leading to the Restoration of Glucose Control
Kaihara, K. A., Dickson, L. M., Ellenbroek, J. H., Orr, C. M. D., Layden, B. T., & Wicksteed, B. (2015) · Diabetes · doi:10.2337/db14-1051 · Cited by 22
“Incretin hormones have also been shown to promote b-cell proliferation and b-cell mass expansion, which has been associated with a rise in b-cell cAMP (17,32,33).”
Thompson, A., Stephens, J. W., Bain, S. C., & Kanamarlapudi, V. (2016) · PLOS ONE · doi:10.1371/journal.pone.0154229 · Cited by 19
Glucagon-like peptide-1 control of GnRH secretion in female sheep
Arbabi, L., Li, Q., Henry, B. A., & Clarke, I. J. (2021) · Journal of Endocrinology · doi:10.1530/joe-20-0335 · Cited by 19
Chen, H., Cao, T., Zhang, B., & Cai, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1097284 · Cited by 18
“When bound to GLP-1, GLP-1R acts through its coupled G protein (Gαs) in pancreatic β-cells, activating adenylyl cyclase and increasing the intracellular levels of cyclic adenosine monophosphate (cAMP) (Doyle and Egan, 2007); this increase in cAMP exerts a series of effects.”
BackgroundDecreased expression of the GLP-1 receptor after segmental artery injury in mice
Bjørnholm, K. D., Povlsen, G. K., Ougaard, M. E., Pyke, C., Rakipovski, G., Tveden-Nyborg, P., Lykkesfeldt, J., & Skovsted, G. F. (2021) · Journal of Endocrinology · doi:10.1530/joe-20-0608 · Cited by 10
GLP-1 mimetics and diabetic ketoacidosis: possible interactions and clinical consequences
Forouzanmehr, B., Hemmati, M. A., Atkin, S. L., Jamialahmadi, T., Yaribeygi, H., & Sahebkar, A. (2025) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-024-03384-1 · Cited by 3
“By this way, consequent insulin production is stimulated in a glucose-dependent manner (Doyle and Egan 2007).”
Metadata
- Authors
- Doyle, M. E., & Egan, J. M.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2007-03
- Volume
- 113
- Issue
- 3
- Pages
- 546-593
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W1012070930
- Cited by
- 680
- References
- 428
- FWCI
- 18.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.